Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arimoclomol in Gaucher Disease Type 1 or 3
NCT03746587Phase 2Terminated
- Sponsor
- Zevra Therapeutics
- Start
- Jun 2018
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of arimoclomol in Gaucher disease type 1 (GD1), Gaucher disease type 3, sponsored by Zevra Therapeutics. Started Jun 2018; status: terminated.
02
Drugs
arimoclomol
03
Conditions
Gaucher disease type 1 (GD1)Gaucher disease type 3
Beyond the preview
Go deeper on NCT03746587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03746587.